Article written by ShareBuyers Editorial Team originally published here As part of the ShareBuyers’ going for growth series, we take a look into the growth prospects of IXICO (IXI), the AIM-listed specialist in AI data analysis for the international clinical trial market which has seen its share price increase by 80% over the past six months.…
IXICO has been featured in S&P Global Market Intelligence's recently published article focused on use of AI technology in drug development. The article entitled 'Big Pharma recruits NASA scientist, sets up command centers in AI push' by Etain Lavelle was originally published here.
IXICO's Associate Director of Technology, Katherine Gray was featured in AMYPAD's recent newsletter to highlight the work she and others within IXICO's tech & data management teams are doing to support AMYPAD projects, using our TrialTracker platform to improve the quality of imaging data.
The comments were made during the following Q&A session with Paul Stevens from BGF’s investment fund, who focuses on identifying opportunities among AIM-listed companies: 1. Can you provide some background on BGF and the sectors/types of companies you invest in?BGF was set up in 2011 to help support small growing companies in the UK.